eXoZymes (EXOZ) Competitors $9.91 -0.29 (-2.84%) As of 07/3/2025 01:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock EXOZ vs. ZYBT, SNDL, AMRN, HRTX, AURA, AQST, OLMA, AVTE, AARD, and LFCRShould you be buying eXoZymes stock or one of its competitors? The main competitors of eXoZymes include Zhengye Biotechnology (ZYBT), SNDL (SNDL), Amarin (AMRN), Heron Therapeutics (HRTX), Aura Biosciences (AURA), Aquestive Therapeutics (AQST), Olema Pharmaceuticals (OLMA), Aerovate Therapeutics (AVTE), Aardvark Therapeutics (AARD), and Lifecore Biomedical (LFCR). These companies are all part of the "pharmaceutical products" industry. eXoZymes vs. Its Competitors Zhengye Biotechnology SNDL Amarin Heron Therapeutics Aura Biosciences Aquestive Therapeutics Olema Pharmaceuticals Aerovate Therapeutics Aardvark Therapeutics Lifecore Biomedical eXoZymes (NASDAQ:EXOZ) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment. Which has preferable valuation & earnings, EXOZ or ZYBT? Zhengye Biotechnology has higher revenue and earnings than eXoZymes. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioeXoZymes$70K1,184.95-$5.86MN/AN/AZhengye Biotechnology$25.53M11.18N/AN/AN/A Is EXOZ or ZYBT more profitable? Company Net Margins Return on Equity Return on Assets eXoZymesN/A N/A N/A Zhengye Biotechnology N/A N/A N/A Does the media prefer EXOZ or ZYBT? In the previous week, Zhengye Biotechnology had 1 more articles in the media than eXoZymes. MarketBeat recorded 5 mentions for Zhengye Biotechnology and 4 mentions for eXoZymes. eXoZymes' average media sentiment score of 1.37 beat Zhengye Biotechnology's score of -0.03 indicating that eXoZymes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment eXoZymes 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zhengye Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryeXoZymes and Zhengye Biotechnology tied by winning 2 of the 4 factors compared between the two stocks. Get eXoZymes News Delivered to You Automatically Sign up to receive the latest news and ratings for EXOZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EXOZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXOZ vs. The Competition Export to ExcelMetriceXoZymesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$82.92M$2.92B$5.55B$9.05BDividend YieldN/A2.44%5.24%4.01%P/E RatioN/A7.9419.5920.21Price / Sales1,184.95281.76418.25119.02Price / CashN/A42.7336.8958.10Price / Book7.937.518.035.67Net Income-$5.86M-$55.14M$3.18B$249.21M7 Day Performance-4.62%4.61%2.93%3.28%1 Month Performance-27.56%4.72%3.75%5.55%1 Year PerformanceN/A5.92%35.20%21.09% eXoZymes Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXOZeXoZymesN/A$9.91-2.8%N/AN/A$82.92M$70K0.0029News CoveragePositive NewsGap DownZYBTZhengye BiotechnologyN/A$6.97-11.5%N/AN/A$328.75M$189.75M0.00278News CoverageLockup ExpirationSNDLSNDL3.669 of 5 stars$1.25+2.0%$3.63+191.2%-34.9%$327.16M$671.81M-4.292,516News CoverageAMRNAmarin0.8912 of 5 stars$15.74-2.8%$12.00-23.7%+18.0%$325.87M$228.61M-4.32360HRTXHeron Therapeutics4.0501 of 5 stars$2.14-0.7%$5.00+134.2%-21.8%$325.72M$144.29M-35.58300News CoverageAURAAura Biosciences1.9042 of 5 stars$6.28-4.5%$22.00+250.6%-4.5%$315.44MN/A-3.3050Positive NewsAQSTAquestive Therapeutics1.3884 of 5 stars$3.15-3.2%$10.14+222.5%+54.4%$312.39M$57.56M-5.33160News CoverageOLMAOlema Pharmaceuticals1.7575 of 5 stars$4.51-5.2%$24.50+443.8%-58.8%$308.23MN/A-2.2470Positive NewsAVTEAerovate TherapeuticsN/A$10.51+0.3%N/A-81.2%$304.63MN/A-3.5220High Trading VolumeAARDAardvark TherapeuticsN/A$14.02-8.8%$31.25+122.9%N/A$304.23MN/A0.0018News CoverageAnalyst RevisionGap UpLFCRLifecore Biomedical1.0488 of 5 stars$8.20-1.6%$8.00-2.5%+62.9%$304.20M$128.26M-5.67690 Related Companies and Tools Related Companies Zhengye Biotechnology Competitors SNDL Competitors Amarin Competitors Heron Therapeutics Competitors Aura Biosciences Competitors Aquestive Therapeutics Competitors Olema Pharmaceuticals Competitors Aerovate Therapeutics Competitors Aardvark Therapeutics Competitors Lifecore Biomedical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXOZ) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eXoZymes Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share eXoZymes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
